AllianceBernstein
ELVN icon

AllianceBernstein’s Enliven Therapeutics ELVN Stock Holding History

AllianceBernstein’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.9M Buy
771,885
+735,045
+1,995% +$20.4M ﹤0.01% 1123
2025
Q4 		$567K Hold
36,840
– – ﹤0.01% 2599
2025
Q3 		$754K Hold
36,840
– – ﹤0.01% 2474
2025
Q2 		$739K Hold
36,840
– – ﹤0.01% 2447
2025
Q1 		$725K Hold
36,840
– – ﹤0.01% 2389
2024
Q4 		$829K Hold
36,840
– – ﹤0.01% 2418
2024
Q3 		$941K Hold
36,840
– – ﹤0.01% 2357
2024
Q2 		$861K Buy
36,840
+20,850
+130% +$439K ﹤0.01% 2387
2024
Q1 		$281K Buy
15,990
+1,020
+7% +$15.6K ﹤0.01% 2819
2023
Q4 		$207K Buy
14,970
+640
+4% +$7.83K ﹤0.01% 2974
2023
Q3 		$196K Buy
+14,330
New +$241K ﹤0.01% 2972

Other funds holding ELVN

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return